PM

Prosight Management Portfolio holdings

AUM $580M Turnover 39.22%
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
-14.49%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$304M
AUM Growth
-$57.5M
Cap. Flow
+$7.69M
Cap. Flow %
2.53%
Top 10 Hldgs %
59.64%
Holding
42
New
6
Increased
17
Reduced
13
Closed
4
Avg Time Held Equity + Options
1.1 years
Top 10 Avg Time Held Equity + Options
0.9 years
Top 20 Avg Time Held Equity + Options
1.1 years
Avg Time Held Equity only
1.1 years
Top 10 Avg Time Held Equity only
0.9 years
Top 20 Avg Time Held Equity only
1.1 years

Top Buys

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$13.6M
2
TECX icon
Tectonic Therapeutic
TECX
+$13M
3
ARGX icon
argenx
ARGX
+$8.65M
4
ISRG icon
Intuitive Surgical
ISRG
+$7.74M
5
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$7.33M

Top Sells

Rank Stock Value
1
ACHC icon
Acadia Healthcare
ACHC
+$15.3M
2
ABCL icon
AbCellera Biologics
ABCL
+$13M
3
BBIO icon
BridgeBio Pharma
BBIO
+$13M
4
ZBH icon
Zimmer Biomet
ZBH
+$8.45M
5
SDGR icon
Schrodinger
SDGR
+$7.55M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CRBP icon
26
Corbus Pharmaceuticals
CRBP
$88.6M
$3.05M 1%
575,136
+305,136
+113% +$2.69M
2024 Q3
2 quarters
CTMX icon
27
CytomX Therapeutics
CTMX
$490M
$2.5M 0.82%
3,930,008
+25,008
+0.6% +$19.4K
2024 Q3
2 quarters
CDNA icon
28
CareDx
CDNA
$3.4B
$2.42M 0.8%
136,593
+56,593
+71% +$1.22M
2024 Q4
1 quarter
BHVN icon
29
Biohaven
BHVN
$1.66B
$2.4M 0.79%
+100,000
New +$3.53M
2025 Q1
0 quarters
ADUS icon
30
Addus HomeCare
ADUS
$2.18B
$2.38M 0.78%
+24,045
New +$2.67M
2025 Q1
0 quarters
SGHT icon
31
Sight Sciences
SGHT
$454M
$2.33M 0.76%
969,287
+60,440
+7% +$170K
2024 Q3
2 quarters
ERAS icon
32
Erasca
ERAS
$5.13B
$1.3M 0.43%
947,110
– –
2023 Q1
8 quarters
SYRE icon
33
Spyre Therapeutics
SYRE
$7.45B
$1.21M 0.4%
74,921
-5,079
-6% -$106K
2024 Q4
1 quarter
OKUR icon
34
OnKure Therapeutics
OKUR
$91.1M
$802K 0.26%
186,570
+122,816
+193% +$691K
2024 Q4
1 quarter
RNTX icon
35
Rein Therapeutics
RNTX
$59.1M
$761K 0.25%
430,000
+25,021
+6% +$52.5K
2024 Q2
3 quarters
MURA icon
36
DELISTED
Mural Oncology
MURA
$533K 0.18%
422,743
-44,079
-9% -$161K
2023 Q4
5 quarters
PLRX icon
37
Pliant Therapeutics
PLRX
$56.4M
$451K 0.15%
+334,263
New +$2.03M
2025 Q1
0 quarters
IMNM icon
38
Immunome
IMNM
$2.04B
$159K 0.05%
23,618
-30,724
-57% -$295K
2024 Q2
3 quarters
CNC icon
39
Centene
CNC
$34.3B
– –
-55,000
Closed -$3.33M –
FTRE icon
40
Fortrea Holdings
FTRE
$2.03B
– –
-55,100
Closed -$1.03M –
LKFT icon
41
CALL
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.92B
– –
-176,900
Closed -$4.86M –
ZBH icon
42
Zimmer Biomet
ZBH
$17.4B
– –
-80,000
Closed -$8.45M –
1
2

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q1 2025 Portfolio in Review

As of Q1 2025, Prosight Management held 42 positions worth $304M, down 16% from $362M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Prosight Management's Q1 2025 filing shows 6 new, 17 increased, 13 reduced and 4 closed positions. Its largest new stake was Tectonic Therapeutic: 398,885 shares worth $7.06M. The largest sale was Acadia Healthcare, an estimated $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

  • Prosight Management's largest Q1 2025 buy was Tectonic Therapeutic: 398,885 shares worth $7.06M.
  • Prosight Management added most to Janux Therapeutics in Q1 2025, an estimated $13.6M increase.
  • Prosight Management's biggest Q1 2025 reduction was Acadia Healthcare, cutting an estimated $15.3M.
  • Prosight Management fully exited Zimmer Biomet in Q1 2025, selling an estimated $8.45M.
  • Prosight Management's ten largest holdings make up 60% of its $304M portfolio in Q1 2025.
  • Prosight Management opened 6 new positions and closed 4 in Q1 2025.
  • Prosight Management's portfolio value fell 16% quarter-over-quarter to $304M.

Based on Prosight Management's 13F filing for Q1 2025, filed 15 May 2025.